Related Experiment Videos
Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the
Hans U Lutz1, Pia Stammler, Valentina Bianchi
1Institute of Biochemistry, Swiss Federal Institute of Technology, ETH-Hönggerberg HPM D 14.1, CH 8093 Zurich, Switzerland. hlutz@bc.biol.ethz.ch
Blood
|September 27, 2003
Summary
Intravenous immunoglobulin (IVIG) therapy effectively reduces complement amplification in dermatomyositis patients. This treatment lowers specific C3b2 complexes, crucial for inflammation, offering a new therapeutic avenue for autoimmune diseases.
Area of Science:
- Immunology
- Complement System Biology
- Autoimmune Disease Pathophysiology
Background:
- Systemic inflammation in autoimmune diseases can stem from overactive complement system amplification loops.
- C3b2-containing complexes are key drivers of complement amplification in circulation.
- Dermatomyositis is a complement-dependent autoimmune disease.
Purpose of the Study:
- To investigate if intravenous normal human immunoglobulin G (IVIG) promotes in vivo inactivation of C3b2-containing complexes.
- To assess the impact of IVIG on complement amplification in dermatomyositis patients.
Main Methods:
- Measurement of C3b2-containing complexes and Factor Bb levels before and during IVIG treatment.
- Quantification of C3 and C4 plasma concentrations at various time points post-IVIG infusion.
- Clinical evaluation of patient response to IVIG therapy.
Main Results:
- IVIG treatment significantly reduced C3b2-containing complexes by 37% after 0.5 g/kg infusion and by 66% by day 14 after 2 g/kg infusion.
- Plasma C3 levels remained stable or increased, while C4 levels were consumed up to 40% post-IVIG.
- Clinical effectiveness was observed in 6 out of 8 dermatomyositis patients.
Conclusions:
- IVIG demonstrates an immediate and sustained inhibitory effect on complement amplification in vivo.
- Despite activating the classical complement pathway, IVIG effectively attenuates the amplification loop in dermatomyositis.
- IVIG shows promise as a therapeutic agent for complement-mediated autoimmune conditions.